Wilms tumor (nephroblastoma), version 2.2021

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth Lisa Tracy, Tamara Vern-Gross, Michael F. WalshAmy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, Miranda Hughes

Research output: Contribution to journalReview articlepeer-review

Abstract

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

Original languageEnglish (US)
Pages (from-to)945-977
Number of pages33
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number8
DOIs
StatePublished - Aug 2021
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Wilms tumor (nephroblastoma), version 2.2021'. Together they form a unique fingerprint.

Cite this